Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Not a member yet
3661 research outputs found
Sort by
Detection and molecular characterization of Chlamydia psittaci and Chlamydia abortus in psittacine pet birds in Buenos Aires province, Argentina
No full textIn order to determine the presence and genetic diversity of Chlamydia spp. in the north-eastern area of Buenos Aires province, Argentina, conjunctival, oropharyngeal, cloacal swab and tissues were collected from a total of 90 psittacine pet birds of different age and clinical manifestations. Through molecular methods, Chlamydiaceae was detected in 30% (27/90) of the samples, out of which 70.3% (19/27) were positive for Chlamydia psittaci and 14.9% (4/27) for Chlamydia abortus. Nine C. psittaci positive samples were genotyped by ompA gene sequences, 8 clustered within genotype A and 1 within genotype B. A significant association was observed between the presence of Chlamydia spp. and the manifestation of clinical signs compatible with chlamydiosis, as well as with the age of the birds (younger than one year old). This report contributes to the improvement of our understanding of chlamydial agents in our country
Detection and molecular characterization of Chlamydia psittaci and Chlamydia abortus in psittacine pet birds in Buenos Aires province, Argentina
No full textIn order to determine the presence and genetic diversity of Chlamydia spp. in the north-eastern area of Buenos Aires province, Argentina, conjunctival, oropharyngeal, cloacal swab and tissues were collected from a total of 90 psittacine pet birds of different age and clinical manifestations. Through molecular methods, Chlamydiaceae was detected in 30% (27/90) of the samples, out of which 70.3% (19/27) were positive for Chlamydia psittaci and 14.9% (4/27) for Chlamydia abortus. Nine C. psittaci positive samples were genotyped by ompA gene sequences, 8 clustered within genotype A and 1 within genotype B. A significant association was observed between the presence of Chlamydia spp. and the manifestation of clinical signs compatible with chlamydiosis, as well as with the age of the birds (younger than one year old). This report contributes to the improvement of our understanding of chlamydial agents in our country
Coccidioidomycosis in Latin America
No full textFil: Canteros, Cristina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio Micosis Profundas; Argentina.Fil: Muñiz-Salazar, Raquel. Universidad Autónoma de Baja California. Escuela de Ciencias de la Salud; México.Fil: Rendon, Adrián. Universidad Autónoma de Nuevo León. Hospital Universitario de Monterrey; México.Fil: Arathoon, Eduardo G. Hospital General San Juan de Dios. Asociación de Salud Integral; Guatemala.Fil: Laniado-Laborín, Rafael. Universdad Autónoma de Baja California. Facultad de Medicina y Psicología; México.Coccidioidomycosis is a highly prevalent systemic mycosis in Latin America and has been reported (human and zoonotic cases) in México, Guatemala, Honduras, Colombia, Venezuela, Brazil, Paraguay, Bolivia, and Argentina. The incidence of coccidioidomycosis in Latin America is unknown due to lack of clinical awareness and limited access to laboratory diagnosis. Coccidioidomycosis is as prevalent in Mexico as in the endemic regions of the United States. The number of cases reported in Brazil and Argentina has progressively increased during the last decade, including areas that were not considered as endemic. Genetic studies have shown that the prevalent species in Latin America is Coccidioides posadasii. Coccidioides immitis has been reported sporadically in indigenous cases from Mexico and Colombia. Coccidioidomycosis and tuberculosis share some risk factors such as immunosuppression and residing in areas endemic for these conditions, so their coexistence in the same patient is not uncommon in Latin America. In most regions, clinical diagnosis of coccidioidomycosis is based on direct sputum examination and histopathology results from biopsies or autopsies. This would explain why primary coccidioidomycosis is rarely diagnosed, and most cases published are about chronic pulmonary or disseminated disease
Multidrug-resistant Escherichia coli harbouring mcr-1 and blaCTX-M genes isolated from swine in Argentina
No full textFil: Faccone, Diego. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Moredo, Fabiana A. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Departamento de Microbiología; Argentina.Fil: Giacoboni, Gabriela. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Departamento de Microbiología; Argentina.Fil: Albornoz, Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Fil: Alarcón, Laura. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Cátedra de Medicina Porcina; Argentina.Fil: Nievas, Victorio F. Universidad Nacional de La Plata. Facultad de Ciencias Veterinarias. Departamento de Microbiología; Argentina.Fil: Corso, Alejandra. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Antimicrobianos; Argentina.Multidrug-resistant Escherichia coli isolates recovered from food-producing animals are a global public-health concern, especially those with transferable mechanisms of antimicrobial resistance such as extended-spectrum β-lactamase (ESBL) and mcr-1 genes. Here we report for the first time E. coli recovered from diarrhoeic and healthy pigs harbouring blaCTX-M and/or mcr-1 from Argentinean farms
PulseNet Latin America and the Caribbean Network: Present and Future
No full textFil: Chinen, Isabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Bacteriología. Servicio Fisiopatogenia; Argentina.Fil: Campos, Josefina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Dorji, Tshewang. Health Emergency Information and Risk Assessment, Health Emergencies Department, Pan American Health Organization/World Health Organization (PAHO/WHO), Washington, District of Columbia; Estados Unidos.Fil: Pérez-Gutiérrez, Enrique. Health Emergency Information and Risk Assessment, Health Emergencies Department, Pan American Health Organization/World Health Organization (PAHO/WHO), Washington, District of Columbia; Estados Unidos.PulseNet Latin America and Caribbean (PNLAC) was established in 2003 and is one of seven Regional networks within PulseNet International. The main objectives of the network are to strengthen national and regional laboratory-based foodborne disease surveillance for early detection and investigation of outbreaks to setup control and prevention strategies in contribution to Public Health. Participants perform standardized pulsed-field gel electrophoresis (PFGE) protocols and analysis. For functioning, it is important for the network, the development of national and regional databases (RDBs) and the communication between countries, regionally and internationally. Metadata from over 8600 cases/outbreaks are profiled and isolated by PFGE and are incorporated into the RDB, hosted by the Pan American Health Organization. Currently PNLAC is moving toward whole-genome sequencing to use as a complementary strategy for surveillance. The aim of this article was to describe the experience of the construction of PNLAC, and its contribution to the surveillance of the foodborne diseases at the country and regional levels
[Fragile X syndrome and other entities associated with the FMR1 gene: Study of 28 affected families]
Get PDFThe fragile X syndrome occurs due to an expansion of CGG trinucleotides, called full mutation, which is found at the Xq27.3 locus of the FMR1 gene. It is the most common cause of inherited intellectual disability. Associated with autistic spectrum disorders in one third of the patients, it affects males with higher prevalence. It also leads to hypermethylation of the gene promoter, silencing it and reducing the expression levels of FMRP, a protein involved in synaptic maturation and plasticity. A lower expansion causes primary ovarian failure syndrome as well as tremor and ataxia syndrome characterized by progressive cerebellar ataxia of late onset and intention tremor. In the present case-control study we analyze the segregation of mutations of the FMR1 gene in different families and the variability of expression that led to the genetic consultation
Frataxin Structure and Function
Get PDFFil: Dain, Liliana. ANLIS Dr.C.G.Malbrán. Centro Nacional de Genética Médica Dr. Eduardo Castilla; Argentina.Mammalian frataxin is a small mitochondrial protein involved in iron sulfur cluster assembly. Frataxin deficiency causes the neurodegenerative disease Friedreich's Ataxia. Valuable knowledge has been gained on the structural dynamics of frataxin, metal-ion-protein interactions, as well as on the effect of mutations on protein conformation, stability and internal motions. Additionally, laborious studies concerning the enzymatic reactions involved have allowed for understanding the capability of frataxin to modulate Fe-S cluster assembly function. Remarkably, frataxin biological function depends on its interaction with some proteins to form a supercomplex, among them NFS1 desulfurase and ISCU, the scaffolding protein. By combining multiple experimental tools including high resolution techniques like NMR and X-ray, but also SAXS, crosslinking and mass-spectrometry, it was possible to build a reliable model of the structure of the desulfurase supercomplex NFS1/ACP-ISD11/ISCU/frataxin. In this chapter, we explore these issues showing how the scientific view concerning frataxin structure-function relationships has evolved over the last years
[Helicobacter cinaedi bacteremia: Presentation of the first cases reported in Argentina]
No full textTwo cases of bacteremia caused by Helicobacter cinaedi are presented. The first case was diagnosed in a 76-year-old male patient, and was secondary to a vascular access device placement; the second case corresponded to a febrile infant of 37 days of life, and was associated with acute gastroenteritis. H. cinaedi is a microorganism difficult to grow in different culture media and also to identify to species level. In both cases, the microscopic observation of blood culture bottles, the use of mass spectrometry and the subsequent sequencing of the hsp60 gene were essential. In the recent literature, H. cinaedi infections are being reported more frequently. In this report we present the first documented cases of bacteremia caused by H. cinaedi in Argentina
Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina
No full textFil: Taverna, Constanza Giselle. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Matias Ezequiel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Bosco-Borgeat, María Eugenia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.Fil: Davel, Graciela Odelsia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Micología; Argentina.The aim of this work was to reidentify strains previously identified as Candida guilliermondii and Candida famata by conventional phenotypic methods conserved in a culture collection from Argentina using ribosomal DNA sequencing, ACT1 gene sequencing, and matrix-assisted laser desorption ionization - time of flight mass spectrometry (MALDI-TOF MS). In addition, we performed antifungal susceptibility tests of eight antifungal drugs commonly used in clinical treatment. We identified 68 isolates belonging to the Candida guilliermondii species complex (59 C. guilliermondii, 8 C. fermentati, and 1 Candida carpophila), 16 isolates belonging to the Candida famata species complex (8 C. famata, 6 Debaryomyces nepalensis, 1 Debaryomyces fabryi, and 1 Debaryomyces tyrocola). Although sequencing of ITS region was able to identify C. guilliermondii and D. nepalensis isolates, sequencing of ACT1 gene seems to be the most appropriate technique for differentiation between C. fermentati and C. carpophila and between members of the C. famata species complex others than D. nepalensis. MALDI-TOF MS has a good potential for the identification of these yeasts, particularly in clinical laboratories since is a rapid and easy to perform technique. Here, we report the first isolation of D. tyrocola from a human patient and the first isolation of D. nepalensis from lungs and blood of human patients. Finally, correct identification and determination of antifungal susceptibility of those closely related species could be a useful tool for clinicians to choose the most effective antifungal treatment
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection
Get PDFFil: Venkatesan, Sudhir. Division of Epidemiology and Public Health, Nottingham; Inglaterra.Fil: Myles, Puja R. Division of Epidemiology and Public Health, Nottingham; Inglaterra.Fil: Bolton, Kirsty J. University of Nottingham. School of Mathematical Sciences, Nottingham; Inglaterra.Fil: Muthuri, Stella G. University College London. MRC Unit for Lifelong Health and Ageing; Inglaterra.Fil: Al Khuwaitir, Tarig. King Saud Medical City. Department of Medicine, Riad; Arabia Saudí.Fil: Anovadiya, Ashish P. Government Medical College and Sir Takhtasinhji General Hospital. Department of Pharmacology, Bhavnagar; India.Fil: Azziz-Baumgartner, Eduardo. Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases. Influenza Division, Atlanta, Georgia; Estados Unidos.Fil: Bajjou, Tahar. Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases. Influenza Division, Atlanta, Georgia; Estados Unidos.Fil: Bassetti, Matteo. University Mohammed V-Souissi. Faculty of Medicine and Pharmacy. Mohammed V Military Teaching Hospital. Biosafety Level 3 and Research Laboratory, Rabat; Marruecos.Fil: Beovic, Bojana. Santa Maria Misericordia Hospital, Údine; Italia.Fil: Bertisch, Barbara. University Medical Center. Department of Infectious Diseases, Liubliana; Eslovenia.Fil: Bonmarin, Isabelle. University of Geneva. Institute of Global Health; Suiza.Fil: Booy, Robert. Institut de Veille Sanitaire, Saint-Maurice; Francia.Fil: Borja-Aburto, Victor H. University of Sydney. Children’s Hospital at Westmead. National Centre for Immunisation Research and Surveillance; Australia.Fil: Burgmann, Heinz. Instituto Mexicano del Seguro Social; México.Fil: Cao, Bin. Medical University of Vienna; Austria.Fil: Carratala, Jordi. Capital Medical University. Beijing Chao-Yang Hospital, Pekín; China.Fil: Chinbayar, Tserendorj. Bellvitge University Hospital. Bellvitge Biomedical Research Institute. Department of Infectious Diseases. Spanish Network for Research in Infectious Diseases, Bellvitge; España.Fil: Cilloniz, Catia. CIBERES. University of Barcelona. August Pi I Sunyer Biomedical Research Institute. Hospital Clinic, Barcelona; España.Fil: Denholm, Justin T. Peter Doherty Institute for Infection and Immunity. Victorian Infectious Diseases Service and Department of Microbiology and Immunology, Parkville, Maryland; Estados Unidos.Fil: Dominguez, Samuel R. University of Colorado School of Medicine. Children’s Hospital Colorado. Department of Pediatric Infectious Diseases, Aurora; Estados Unidos.Fil: Duarte, Pericles A. D. Universidade Estadual do Oeste do Paraná–UNIOESTE, Cascavel; Brasil.Fil: Dubnov-Raz, Gal. Sheba Medical Center. Edmond and Lily Safra Children’s Hospital, Ramat Gan; Israel.Fil: Fanella, Sergio. University of Manitoba. Section of Pediatric Infectious Diseases, Winnipeg; Canadá.Fil: Gao, Zhancheng. Peking University People’s Hospital. Department of Respiratory and Critical Care Medicine, Pekín; China.Fil: Gérardin, Patrick. Pôle Femme Mère Enfant; Francia.Fil: Giannella, Maddalena. University of Bologna. Sant’Orsola Malpighi Hospital. Department of Clinical and Surgical Sciences, Bolonia; Italia.Fil: Gubbels, Sophie. Statens Serum Institut. Sector for National Health Documentation and Research. Department of Infectious Disease Epidemiology, Copenhagen; Dinamarca.Fil: Herberg, Jethro. Imperial College. Division of Infectious Disease. Section of Paediatrics, Londres; Inglaterra.Fil: Higuera Iglesias, Anjarath Lorena. Instituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosío Villegas. Department of Research in Clinical Epidemiology, Ciudad de México; México.Fil: Hoeger, Peter H. Catholic Children’s Hospital Wilhelmstift, Hamburgo; Alemania.Fil: Hu, Xiao Yun. Peking Union Medical College Hospital, Pekín; China.Fil: Islam, Quazi T. Dhaka Medical College Hospital, Bangladés; Asia del Sur.Fil: Jiménez, Mirela F. Preceptora da Residência Médica do Hospital Fêmina. Departamento de Ginecologia e Obstetrícia–UFCSPA, Fêmina; Brasil.Fil: Keijzers, Gerben. Gold Coast University Hospital, Gold Coast; Australia.Fil: Khalili, Hossein. Tehran University of Medical Sciences. Faculty of Pharmacy. Department of Clinical Pharmacy, Teherán; Irán.Fil: Kusznierz, Gabriela F. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Respiratorias; Argentina.Fil: Kuzman, Ilija. University of Zagreb School of Medicine. University Hospital for Infectious Diseases; Croacia.Fil: Langenegger, Eduard. Stellenbosch University–Tygerberg. Department of Obstetrics and Gynaecology,, Ciudad del Cabo; Sudáfrica.Fil: Lankarani, Kamran B. Shiraz University of Medical Sciences. Health Policy Research Center, Shiraz; Irán.Fil: Leo, Yee-Sin. Tan Tock Seng Hospital. Department of Infectious Diseases; Singapur.Fil: Libster, Romina. Vanderbilt University. Department of Pediatrics, Nashville, Tennessee; Estados Unidos.Fil: Linko, Rita. Helsinki University Hospital; Finlandia.Fil: Madanat, Faris. King Hussein Cancer Center. Department of Pediatrics, Amán: Jordania.Fil: Maltezos, Efstratios. Democritus University Thrace. University General Hospital of Alexandroupolis. Unit of Infectious Diseases; Grecia.Fil: Mamun, Abdullah. British Columbia Centre for Disease Control, Vancouver; Canadá.Fil: Manabe, Toshie. Teikyo University School of Medicine. Department of Hygiene and Public Health, Tokyo; Japón.Fil: Metan, Gokhan. Hacettepe University. Faculty of Medicine. Department of Infectious Diseases and Clinical Microbiology, Angora; Turquía.Fil: Mickiene, Auksė. Lithuanian University of Health Sciences, Kaunas; Lituania.Fil: Mikić, Dragan. University of Bergen. Department of Clinical Science. Influenza Center; Noruega.Fil: Mohn, Kristin G. I. University of Bergen. Department of Clinical Science. Influenza Center; Noruega.Fil: Oliva, Maria E. Hospital San Martín de Paraná. Departamento de Control de Infecciones, Entre Ríos; Argentina.Fil: Ozkan, Mehpare. Bahçeşehir University. Pediatric Neurology Department; Turquía.Fil: Parekh, Dhruv. University of Birmingham. Institute of Inflammation and Ageing. Respiratory and Critical Care Medicine, Birmingham; Inglaterra.Fil: Paul, Mical. Rambam Health Care Campus. Division of Infectious Diseases, Haifa; Israel.Fil: Rath, Barbara A. Charité–University Medical Center Berlin. Department of Pediatrics, Berlín; Alemania.Fil: Refaey, Samir. Ministry of Health and Population. Epidemiology and Surveillance Department, El Cairo; Egipto.Fil: Rodríguez, Alejandro H. IISPV-URV-CIBERES. Hospital Joan XXIII. Critical Care Department, Tarragona; España.Fil: Sertogullarindan, Bunyamin. Yuzuncu Yil University. Medical Faculty, Department of Pulmonary Medicine, Van; Turquía.Fil: Skręt-Magierło, Joanna. Uniwersytet Rzeszowski, Rzeszow; Polonia.Fil: Somer, Ayper. Istanbul University. Istanbul Medical Faculty. Department of Pediatric Infectious Diseases, Estambul; Turquía.Fil: Talarek, Ewa. Medical University of Warsaw,. Department of Children`s Infectious Diseases, Varsovia; Polonia.Fil: Tang, Julian W. University of Leicester. Department of Respiratory Sciences; Inglaterra.Fil: To, Kelvin. University of Hong Kong. Queen Mary Hospital. Department of Microbiology. Carol Yu Centre for Infection and Division of Infectious Diseases, Hong Kong Special Administrative Region; China.Fil: Tran, Dat. Oregon Health Authority. Public Health Division. Acute and Communicable Disease Prevention, Portland; Estados Unidos.Fil: Uyeki, Timothy M. Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases. Influenza Division, Atlanta, Georgia; Estados Unidos.Fil: Vaudry, Wendy. University of Alberta. Stollery Children’s Hospital. Department of Pediatrics. Division of Infectious Diseases, Edmonton; Canadá.Fil: Vidmar, Tjasa. General Hospital Slovenj Gradec, Slovenj Gradec; Eslovenia.Fil: Zarogoulidis, Paul. Aristotle University of Thessaloniki. “G. Papanikalaou” General Hospital. Pulmonary Department, Salónica; Grecia.Fil: Nguyen-Van-Tam, Jonathan S. Division of Epidemiology and Public Health, Nottingham; Inglaterra.Fil: PRIDE Consortium Investigators. University of Nottingham; Inglaterra.Background. The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear.
Methods. We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects
negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded.
Results. We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI,.78–.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS.
Conclusions. When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment